| 项目编号 |
PRJCA038556 |
| 项目标题 |
The results of APICAL-GC cohort |
| 涉及领域 |
Medical |
| 数据类型 |
Variation
|
| 物种名称 |
Homo sapiens
|
| 描述信息 |
Efficacy and safety of anlotinib plus toripalimab as a first-line treatment regimen for advanced gastric cancer in patients with performance status 2 (APICAL-GC): an open-label, single-arm, phase II trial |
| 样品范围 |
Multiisolate |
| 发布日期 |
2025-04-11 |
| 出版信息 |
| PubMed ID |
文章标题 |
杂志名称 |
Doi |
发表年份 |
| 40450051
|
Anlotinib plus toripalimab as a first-line treatment in patients with advanced gastric cancer and performance status 2: the phase II APICAL-GC trial
|
Nature Communications
|
10.1038/s41467-025-60317-z
|
2025
|
|
|
| 项目资金来源 |
| 机构 |
项目类型 |
授权项目ID |
授权项目名称 |
| Chinese National Natural Science Funding
|
|
82172710-2021
|
|
| Innovation Clinical Research Project of Shanghai Changzheng Hospital
|
|
2020YLCYJ-Z03-2020
|
|
|
|
| 提交者 |
Dongyu
Liu (dongyu.liu@3dmedcare.com)
|
| 提交单位 |
3D Medicines Inc. |
| 提交日期 |
2025-04-11 |
